Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) saw strong trading volume on Monday . 59,708 shares were traded during mid-day trading, an increase of 19% from the previous session’s volume of 50,010 shares.The stock last traded at $5.17 and had previously closed at $5.29.

Several research analysts have commented on the company. BMO Capital Markets assumed coverage on Tokai Pharmaceuticals in a research report on Monday, April 11th. They issued an “outperform” rating and a $11.00 price objective on the stock. Janney Montgomery Scott assumed coverage on Tokai Pharmaceuticals in a research report on Wednesday, April 6th. They issued a “buy” rating on the stock. Finally, Bank of America Corp. assumed coverage on Tokai Pharmaceuticals in a research report on Wednesday, April 6th. They issued a “buy” rating and a $16.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $18.00.

The stock has a 50 day moving average price of $5.76 and a 200 day moving average price of $6.29. The firm’s market cap is $115.77 million.

Tokai Pharmaceuticals (NASDAQ:TKAI) last issued its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by $0.01. On average, equities research analysts predict that Tokai Pharmaceuticals Inc. will post ($2.00) EPS for the current year.

Tokai Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of second-generation androgen signaling inhibitors, while also introducing a third mechanism-androgen receptor degradation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.